Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Defactinib (VS-6063) Combined With VS-6766 (CH5126766) in Patients With Metastatic Uveal Melanoma

NCT04720417 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT04720417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04720417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Defactinib (VS-6063) Combined With VS-6766 (CH5126766) in Patients With Metastatic Uveal Melanoma
Lead sponsor
Thomas Jefferson University
Phase
Phase 2
Overall status
Terminated
Start date
January 26, 2021
Completion date
April 30, 2024
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma